-
公开(公告)号：US20220194955A1
公开(公告)日：2022-06-23
申请号：US17552016
申请日：2021-12-15
Applicant: AMGEN INC.
Inventor： Shon BOOKER , Matthew Paul BOURBEAU , John R. BUTLER , Sanne Ormholt Schroder GLAD , Brian Alan LANMAN , Patricia LOPEZ , Francesco MANONI , Liping H. PETTUS , Ian SARVARY , Nuria A. TAMAYO , Mikkel VESTERGAARD , Nicholas Anthony WEIRES
IPC: C07D491/06 , C07D491/16 , C07D471/06 , C07D471/16 , A61P35/00
Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure:
-
公开(公告)号：US20240124442A1
公开(公告)日：2024-04-18
申请号：US18264216
申请日：2022-02-03
Applicant: AMGEN INC.
Inventor： Albert AMEGADZIE , Diane Jennifer BEYLKIN , Shon BOOKER , Matthew Paul BOURBEAU , John R. BUTLER , Kevin Lloyd GREENMAN , Todd J. KOHN , Kexue LI , Qingyian LIU , Ana Elena MINATTI , Primali Vasundera NAVARATNE , Liping H. PETTUS , Rene RAHIMOFF , Hui-Ling WANG , Nicholas Anthony WEIRES
IPC: C07D471/04 , A61P35/00 , C07D471/14 , C07D491/048 , C07D491/147 , C07D495/04 , C07D498/04 , C07D519/00
CPC classification number: C07D471/04 , A61P35/00 , C07D471/14 , C07D491/048 , C07D491/147 , C07D495/04 , C07D498/04 , C07D519/00
Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure:
-
公开(公告)号：US20220363694A1
公开(公告)日：2022-11-17
申请号：US17266466
申请日：2019-08-13
Applicant: Amgen Inc. , Carmot Therapeutics, Inc.
Inventor： John R. BUTLER , Daniel ERLANSON , Russell GRACEFFA , Jeffrey IWIG , Joon Won JEONG , Ryan D. WHITE , Yongwei WU , Shuyan YI , Xiao Mei ZHENG , Jesse M. MCFARLAND , Abhisek BANERJEE
IPC: C07D519/00 , C07D487/18
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
-
公开(公告)号：US20240101570A1
公开(公告)日：2024-03-28
申请号：US18255575
申请日：2021-11-22
Applicant: AMGEN INC.
Inventor： Albert AMEGADZIE , Diane Jennifer BEYLKIN , Shon BOOKER , Matthew Paul BOURBEAU , John R. BUTLER , Sanne Ormholt Schroder GLAD , Todd J. KOHN , Brian Alan LANMAN , Kexue LI , Qingyian LIU , Patricia LOPEZ , Francesco MANONI , Primali Vasundera NAVARATNE , Liping H. PETTUS , Rene RAHIMOFF , Nuria A. TAMAYO , Mikkel VESTERGAARD , Hui-Ling WANG , Nicholas Anthony WEIRES
IPC: C07D491/048 , A61K35/00 , C07D401/12 , C07D401/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D491/147 , C07D495/04 , C07D498/04 , C07D519/00
CPC classification number: C07D491/048 , A61K35/00 , C07D401/12 , C07D401/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D491/147 , C07D495/04 , C07D498/04 , C07D519/00
Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).
-
Patent Agency Ranking
公开(公告)号：US20230159510A1
公开(公告)日：2023-05-25
申请号：US17799077
申请日：2021-02-11
Applicant: AMGEN INC.
Inventor： Jennifer Rebecca ALLEN , Albert AMEGADZIE , Diane Jennifer BEYLKIN , Shon BOOKER , Matthew Paul BOURBEAU , John R. BUTLER , Michael J. FROHN , Sanne Ormholt Schroder GLAD , Birgitte Weinreich HUSEMOEN , Matthew R. KALLER , Todd J. KOHN , Brian Alan LANMAN , Kexue LI , Qingyian LIU , Patricia LOPEZ , Vu Van MA , Francesco MANONI , Jose MEDINA , Ana Elena MINATTI , Jorge PEIRO CADAHIA , Liping PETTUS , Alexander J. PICKRELL , Ian SARVARY , Nuria A. TAMAYO , Mikkel VESTERGAARD
IPC: C07D413/14 , C07D471/04 , C07D401/14 , C07D401/12 , C07D405/14
CPC classification number: C07D413/14 , C07D401/12 , C07D401/14 , C07D405/14 , C07D471/04
Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure: (I)
-
公开(公告)号：US20140371201A1
公开(公告)日：2014-12-18
申请号：US14302337
申请日：2014-06-11
Applicant: AMGEN INC.
Inventor： Matthew WEISS , Alessandro BOEZIO , Christiane BOEZIO , John R. BUTLER , Margaret Yuhua CHU-MOYER , Erin F. DIMAURO , Thomas DINEEN , Russell GRACEFFA , Angel GUZMAN-PEREZ , Hongbing HUANG , Charles KREIMAN , Daniel LA , Isaac E. MARX , Benjamin Charles MILGRIM , Hanh Nho NGUYEN , Emily PETERSON , Karina ROMERO , Brian SPARLING
IPC: C07D471/04 , C07D401/12 , C07D215/227 , C07D417/12 , C07C53/18 , C07D413/12 , C07D413/14
CPC classification number: C07D417/14 , C07C53/18 , C07D215/227 , C07D215/36 , C07D241/44 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐，其是电压门控钠通道的抑制剂，特别是Nav1.7。 该化合物可用于治疗与钠通道活性相关的疾病，例如疼痛障碍和瘙痒。 还提供含有本发明化合物的药物组合物。
-
公开(公告)号：US20240092794A1
公开(公告)日：2024-03-21
申请号：US18502780
申请日：2023-11-06
Applicant: AMGEN INC.
Inventor： Shon BOOKER , Matthew Paul BOURBEAU , John R. BUTLER , Sanne Ormholt Schroder GLAD , Brian Alan LANMAN , Patricia LOPEZ , Francesco MANONI , Liping H. PETTUS , Ian SARVARY , Nuria A. TAMAYO , Mikkel VESTERGAARD , Nicholas Anthony WEIRES
IPC: C07D491/06 , A61P35/00 , C07D471/06 , C07D471/16 , C07D491/16
CPC classification number: C07D491/06 , A61P35/00 , C07D471/06 , C07D471/16 , C07D491/16
Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure:
-
公开(公告)号：US20190167682A1
公开(公告)日：2019-06-06
申请号：US16319783
申请日：2017-07-20
Applicant: AMGEN INC.
Inventor： Matthew WEISS , John R. BUTLER , Benjamin Charles MILGRAM , Gwenaella RESCOURIO , Alessandro BOEZIO , Brian Andrew SPARLING , Daniel LA
IPC: A61K31/506 , A61P25/00 , A61K31/4439
CPC classification number: A61K31/506 , A61K31/4439 , A61P25/00 , C07D213/75 , C07D401/12 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
-
公开(公告)号：US20160046626A1
公开(公告)日：2016-02-18
申请号：US14920833
申请日：2015-10-22
Applicant: AMGEN INC.
Inventor： Matthew WEISS , Alessandro BOEZIO , Christiane BOEZIO , John R. BUTLER , Margaret Yuhua CHU-MOYER , Erin F. DIMAURO , Thomas DINEEN , Russell GRACEFFA , Angel GUZMAN-PEREZ , Hongbing HUANG , Charles KREIMAN , Daniel LA , Isaac E. MARX , Benjamin Charles MILGRAM , Hanh Nho NGUYEN , Emily Anne PETERSON , Karina R. VAIDA , Brian SPARLING
IPC: C07D471/04 , C07D417/12 , C07D413/14 , C07D413/12 , C07D401/12
CPC classification number: C07D417/14 , C07C53/18 , C07D215/227 , C07D215/36 , C07D241/44 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐，其是电压门控钠通道的抑制剂，特别是Nav1.7。 该化合物可用于治疗与钠通道活性相关的疾病，例如疼痛障碍和瘙痒。 还提供含有本发明化合物的药物组合物。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.032 seconds)
